Within Discredited Stem Cell Research, a True Scientific First
By Nicholas Wade,
New York Times
| 08. 03. 2007
The world of stem cell research was set reeling two years ago when its most successful practitioner, the Korean scientist Hwang Woo Suk, was found to have fabricated much of his work. But according to a new post-mortem of his research, he did achieve a scientific first, though not the one he claimed.
Dr. Hwang said he had derived embryonic stem cells from the adult cells of a patient, but the claim was discredited after parts of his research were found to have been faked. A team of Boston scientists has now re-examined stocks of Dr. Hwang's purported embryonic stem cells and arrived at a surprising conclusion: His embryonic stem cells were the product of parthenogenesis, or virgin birth, meaning they were derived from an unfertilized egg.
A team led by Kitai Kim and George Q. Daley of Children's Hospital Boston reports this conclusion today in the journal Cell Stem Cell.
Embryonic stem cells derived through parthenogenesis cannot develop normally, so they are free of ethical objections. The cells could perhaps help treat degenerative diseases in women capable of...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
